{
    "nct_id": "NCT04555811",
    "official_title": "FATE FT596 With Rituximab as Relapse Prevention in High Risk Patients After Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma",
    "inclusion_criteria": "* Diagnosis of diffuse large B cell lymphoma or aggressive (high-grade) B-cell lymphoma for which an autologous stem cell transplant is planned or recently completed\n* High risk for relapse defined as at least one of the below:\n\n  * Primary induction failure (no complete or partial remission at any point after diagnosis\n  * Initial remission duration < 12 months\n  * Lack of complete metabolic (PET scan) response after 2-3 cycles of salvage chemotherapy\n  * Evidence of c-myc and bcl-2 and/or bcl-6 re-arrangement (double hit or triple hit lymphoma)\n  * Age-adjusted IPI 2-3 at relapse\n* Age 18 years or older at the time of signing consent.\n* Agrees to use adequate contraception (or evidence of sterility) for at least 12 months after the last dose of rituximab.\n* Agrees and signs the separate consent for up to 15 years of follow-up (Long-term Follow-up study CPRC#2020LS052)\n* Provides voluntary written consent prior to the performance of any research related activities.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of any investigational therapy within 28 days prior to the first dose of FT596 or planned use of an investigational therapy during the first 100 days after transplant\n* Planned post-transplant irradiation prior to Day +100\n* Seropositive for HIV, active Hepatitis B or C infection with detectable viral load by PCR\n* Body weight <50kg\n* Known allergy to the following FT596 components: albumin (human) or DMSO\n* Unable to receive rituximab\n\nPost-HSCT Reconfirmation of eligibility\n\n* No life-threatening medical issues (i.e. ongoing Grade 4 adverse events) where, in the opinion of the treating investigator, use of FT596 is not in the patient's best interest.\n* No active uncontrolled infection.\n* Adequate organ function post-transplant including:\n\n  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 x ULN (Grade 2 CTCAE v5)\n  * total bilirubin ≤1.5 x ULN (Grade 1 CTCAE v5)\n  * serum creatinine ≤1.5 x ULN (Grade 1 CTCAE v5)\n  * oxygen saturation ≥93% on room air\n* For Day 30 dosing only - CBC requirement consistent with engraftment (ANC>500, platelet>20,000 without transfusion support within previous 7 days). There are no CBC parameters for Day 7 dosing.\n* No requirement for systemic immunosuppressive therapy (> 5mg prednisone daily) during the FT596 dosing period.",
    "miscellaneous_criteria": ""
}